HJ SCIENCE-B

HJ Science Co., Ltd. is a biotechnology company engaged in the research and development of new small molecule drugs. It focuses on metabolic diseases, oncology, and autoimmune disorders. Its core pipeline includes HJ787, a selective TYK2 inhibitor for atopic dermatitis and acne vulgaris; HJ178, an oral agent for type 2 diabetes; and HJ891, an oral KRAS inhibitor and intravenous injection for non-small-cell lung cancer. The company is also developing HJ197 in clinical-stage for hepatocellular carcinoma, and five preclinical candidates—HJ356, HJ093, HJ199, HJ198, and HJ086—for cardiovascular disease, atherosclerosis, and solid tumors. Founded in 2017, it is based in Chengdu, China.